Skip to main content

Advertisement

Log in

Vasculitis associated with immune checkpoint inhibitors—a systematic review

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Recent experimental and genetic studies have implicated the role of programmed cell death protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in the pathogenesis of medium and large vessel vasculitis. This study sought to evaluate the occurrence and nature of vasculitis associated with cancer treatment using immune checkpoint inhibition (anti-PD-1, anti-PDL-1, and anti-CTLA4). A systematic review of the medical literature was conducted by searching all available clinical data up to February 2018 in several databases and search engines including Cochrane Library, Embase, Google Scholar, Medline, Scopus, Web of Science, and Clinicaltrials.gov. Searches included the following FDA-approved anti-PD1 (nivolumab and pembrolizumab), anti-PDL1 (atezolizumab, avelumab, and durvalumab), and anti-CTLA4 (ipilimumab). The vasculitis cases were compiled and classified based on the 2012 revised Chapel Hill Consensus Conference nomenclature. The clinical feature of the vasculitis cases and their relationship to immune checkpoint inhibition was assessed. There were 53 cases of vasculitis of which 20 were confirmed. The main reported type of vasculitis was large vessel vasculitis and vasculitis of the central and peripheral nervous system. All cases resolved with either holding the immune checkpoint inhibitors and/or administering glucocorticoids. No death related to vasculitis was reported. Vasculitis, namely large vessel and vasculitis of the nervous system, is associated with immune checkpoint inhibition. Results of this study add to the growing evidence regarding the relationship between immune checkpoints and vasculitis and suggest that the pathway may be a therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yang Y (2015) Cancer immunotherapy harnessing the immune system to battle cancer. J Clin Invest 125:3335–3337

    Article  PubMed  PubMed Central  Google Scholar 

  2. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK et al (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118:499–509

    Article  PubMed  CAS  Google Scholar 

  3. Caspi RR (2008) Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 8:970–976

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One 11:e0160221

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168

    Article  PubMed  Google Scholar 

  6. Zhang H, Watanabe R, Berry GJ, Vaglio A, Liao YJ, Warrington KJ, Goronzy JJ, Weyand CM (2017) Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 114:E970–EE79

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD et al (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investig New Drugs 29:489–498

    Article  CAS  Google Scholar 

  9. Minor DR, Bunker SR, Doyle J (2013) Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab. J Clin Oncol 31:e356

    Article  PubMed  Google Scholar 

  10. Goldstein BL, Gedmintas L, Todd DJ (2014) Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66:768–769

    Article  PubMed  Google Scholar 

  11. Manusow JS, Khoja L, Pesin N, Joshua AM, Mandelcorn ED (2014) Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer 2:41

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pinkston O FB, Wang B (2016) Type and frequency of immune-related adverse reactions in patients treated with pembrolizumab (keytruda), a monoclonal antibody directed against PD-1, in advanced melanoma at a single institution

  13. Liao B, Wang W, Hammack J, Mauermann M (2016) Vasculitic neuropathy in the setting of nivolumab therapy for metastatic mesothelioma. Ann Neurol 80:M279

    Google Scholar 

  14. Aya F, Ruiz-Esquide V, Viladot M, Font C, Prieto-Gonzalez S, Prat A et al (2017) Vasculitic neuropathy induced by pembrolizumab. Ann Oncol 28:433–434

    PubMed  CAS  Google Scholar 

  15. van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal C, de Groot DJ et al (2016) Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 55:1143–1145

    Article  Google Scholar 

  16. Bender C, Dimitrakopoulou-Strauss A, Enk A, Hassel JC (2016) Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment. Ann Oncol 27:1353–1354

    Article  PubMed  CAS  Google Scholar 

  17. Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N et al (2016) Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4:175–178

    Article  PubMed  Google Scholar 

  18. Arellano K, Mosley JC 3rd, Moore DC (2018) Case report of ipilimumab-induced diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis. J Pharm Pract 31:227–229

    Article  PubMed  Google Scholar 

  19. Roy AK, Tathireddy HR, Roy M (2017) Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. BMJ Case Rep:2017

  20. Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216–1222

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cappelli LC, Shah AA, Bingham CO 3rd (2017) Immune-related adverse effects of cancer immunotherapy—implications for rheumatology. Rheum Dis Clin N Am 43:65–78

    Article  Google Scholar 

  22. Laubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S et al (2017) Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer 5:46

    Article  PubMed  PubMed Central  Google Scholar 

  23. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44

    Article  PubMed  CAS  Google Scholar 

  24. Ban BH CJ, Graham RM (2017) Rheumatology case report immune-related aortitis associated with ipilimumab. The Rheumatologist 2017

  25. Sun R, Danlos FX, Ammari S, Louvel G, Dhermain F, Champiat S, Lambotte O, Deutsch E (2017) Anti-PD-1 vasculitis of the central nervous system or radionecrosis? J Immunother Cancer 5:96

    Article  PubMed  PubMed Central  Google Scholar 

  26. Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L (2018) Ipilimumab induced digital vasculitis. J Immunother Cancer 6:12

    Article  PubMed  PubMed Central  Google Scholar 

  27. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65:1–11

    Article  PubMed  CAS  Google Scholar 

  28. Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM (2017) Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol 312:H1052–H1H59

    Article  PubMed  PubMed Central  Google Scholar 

  29. Watson AM, Prasad KM, Klei L, Wood JA, Yolken RH, Gur RC et al (2013) Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med 43:1023–1031

    Article  PubMed  CAS  Google Scholar 

  30. Chun JK, Kang DW, Yoo BW, Shin JS, Kim DS (2010) Programmed death-1 (PD-1) gene polymorphisms lodged in the genetic predispositions of Kawasaki Disease. Eur J Pediatr 169:181–185

    Article  PubMed  CAS  Google Scholar 

  31. Sakthivel P, Giscombe R, Ramanujam R, Lefvert AK (2009) Polymorphisms in PDCD1 gene are not associated with Wegener’s granulomatosis. Rheumatol Int 29:1247–1250

    Article  PubMed  CAS  Google Scholar 

  32. Giscombe R, Wang X, Huang D, Lefvert AK (2002) Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener’s granulomatosis. J Rheumatol 29:950–953

    PubMed  CAS  Google Scholar 

  33. Kamesh L, Heward JM, Williams JM, Gough SC, Chavele KM, Salama A et al (2009) CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology (Oxford) 48:1502–1505

    Article  CAS  Google Scholar 

  34. Meng Q, Guo H, Hou S, Jiang Z, Kijlstra A, Yang P (2011) Lack of an association of PD-1 and its ligand genes with Behcet’s disease in a Chinese Han population. PLoS One 6:e25345

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Direskeneli H, Tuna-Erdogan E, Gunduz F, Bandurska-Luque A, Alparslan B, Kebe M et al (2012) PDCD1 polymorphisms are not associated with Takayasu’s arteritis in Turkey. Clin Exp Rheumatol 30:S11–S14

    PubMed  Google Scholar 

  36. Veitch D, Tsai T, Watson S, Joshua F (2014) Paraneoplastic polyarteritis nodosa with cerebral masses: case report and literature review. Int J Rheum Dis 17:805–809

    Article  PubMed  Google Scholar 

  37. Anastasakis A, Dick AD, Damato EM, Spry PG, Majid MA (2011) Cancer-associated retinopathy presenting as retinal vasculitis with a negative ERG suggestive of on-bipolar cell pathway dysfunction. Doc Ophthalmol 123:59–63

    Article  PubMed  Google Scholar 

  38. Okada M, Suzuki K, Hidaka T, Shinohara T, Takada K, Nakajima M et al (2002) Polyarteritis associated with hypopharyngeal carcinoma. Intern Med 41:892–895

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anisha Daxini.

Ethics declarations

The manuscript does not contain clinical studies or patient data information.

Disclosures

None.

Additional information

Key point messages

- Vasculitis, predominantly large vessel vasculitis and vasculitis of the nervous system, can occur in patients treated with immune checkpoint inhibitors and should be suspected in those presenting with suggestive clinical features.

- The findings of this study add to the growing evidence on the relationship between programmed cell death protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) pathways and large and medium vessel vasculitis.

- PD-1/PDL-1 and CTLA-4 pathways can be a therapeutic target for the treatment of medium and large vessel vasculitis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daxini, A., Cronin, K. & Sreih, A.G. Vasculitis associated with immune checkpoint inhibitors—a systematic review. Clin Rheumatol 37, 2579–2584 (2018). https://doi.org/10.1007/s10067-018-4177-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4177-0

Keywords

Navigation